Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Read more about Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Read more about 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Read more about Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)': Annals of Oncology, Volume Read more about Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)': Annals of Oncology, Volume
Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial. Read more about Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial.
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Read more about Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.
Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer. Read more about Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer.
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Read more about Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.
Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. Read more about Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients.
Solid organ transplant rejection associated with immune-checkpoint inhibitors. Read more about Solid organ transplant rejection associated with immune-checkpoint inhibitors.
